$ANAB
AnaptysBio Inc

2019 Q3 Form 10-Q Financial Statement

#000137005319000027 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $5.000M $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.810M $4.310M $3.830M
YoY Change -4.75% 12.53% 62.98%
% of Gross Profit
Research & Development $29.93M $27.35M $10.58M
YoY Change 67.37% 158.43% 46.88%
% of Gross Profit
Depreciation & Amortization $130.0K $120.0K $70.00K
YoY Change 44.44% 71.43% 40.0%
% of Gross Profit
Operating Expenses $33.75M $31.66M $14.42M
YoY Change 54.18% 119.61% 50.86%
Operating Profit -$33.75M -$26.66M -$14.42M
YoY Change 99.83% 84.93% 464.19%
Interest Expense $240.0K $281.0K $436.0K
YoY Change -40.0% -35.55% -0.68%
% of Operating Profit
Other Income/Expense, Net $2.661M $2.635M $797.0K
YoY Change 186.44% 230.61% -717.83%
Pretax Income -$31.08M -$24.02M -$13.62M
YoY Change 94.79% 76.4% 408.13%
Income Tax -$51.00K -$60.00K $0.00
% Of Pretax Income
Net Earnings -$31.03M -$23.96M -$13.62M
YoY Change 94.47% 75.96% 407.38%
Net Earnings / Revenue -479.24%
Basic Earnings Per Share -$1.15 -$0.89 -$0.57
Diluted Earnings Per Share -$1.15 -$0.89 -$0.57
COMMON SHARES
Basic Shares Outstanding 27.05M shares 27.02M shares 23.50M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $421.0M $422.2M $267.9M
YoY Change -14.74% 57.6% 151.89%
Cash & Equivalents $182.9M $146.6M $57.06M
Short-Term Investments $238.1M $275.7M $210.9M
Other Short-Term Assets $3.600M $3.800M $3.800M
YoY Change -10.0% 0.0% -2.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $424.6M $431.0M $271.8M
YoY Change -15.59% 58.56% 134.63%
LONG-TERM ASSETS
Property, Plant & Equipment $1.695M $1.481M $1.086M
YoY Change 26.12% 36.37% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $23.40M $45.70M $32.70M
YoY Change 25.81% 39.76% 135.25%
Other Assets $1.735M $1.913M $322.0K
YoY Change 2096.2% 494.1% 222.0%
Total Long-Term Assets $26.91M $49.16M $34.20M
YoY Change 33.88% 43.75% 134.86%
TOTAL ASSETS
Total Short-Term Assets $424.6M $431.0M $271.8M
Total Long-Term Assets $26.91M $49.16M $34.20M
Total Assets $451.5M $480.1M $306.0M
YoY Change -13.69% 56.9% 134.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.52M $10.92M $4.426M
YoY Change 70.26% 146.75% 18.85%
Accrued Expenses $15.29M $14.10M $4.837M
YoY Change 113.94% 191.54% 49.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.100M $4.800M $7.500M
YoY Change -58.67% -36.0% 141.94%
Total Short-Term Liabilities $29.73M $30.62M $16.79M
YoY Change 42.43% 82.39% 66.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $4.100M
YoY Change -100.0% -100.0% -62.73%
Other Long-Term Liabilities $883.0K $1.105M $100.0K
YoY Change 341.5% 1005.0% -50.0%
Total Long-Term Liabilities $883.0K $1.105M $4.200M
YoY Change -66.04% -73.69% -62.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.73M $30.62M $16.79M
Total Long-Term Liabilities $883.0K $1.105M $4.200M
Total Liabilities $30.61M $31.73M $21.00M
YoY Change 30.82% 51.09% -0.94%
SHAREHOLDERS EQUITY
Retained Earnings -$223.8M -$192.7M -$113.7M
YoY Change 72.53% 69.51% 64.54%
Common Stock $27.00K $27.00K $24.00K
YoY Change 0.0% 12.5% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $420.9M $448.4M $285.0M
YoY Change
Total Liabilities & Shareholders Equity $451.5M $480.1M $306.0M
YoY Change -13.69% 56.9% 134.66%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$31.03M -$23.96M -$13.62M
YoY Change 94.47% 75.96% 407.38%
Depreciation, Depletion And Amortization $130.0K $120.0K $70.00K
YoY Change 44.44% 71.43% 40.0%
Cash From Operating Activities -$22.09M -$15.52M -$8.880M
YoY Change 48.65% 74.77% 236.36%
INVESTING ACTIVITIES
Capital Expenditures -$280.0K -$240.0K -$310.0K
YoY Change -12.5% -22.58% 416.67%
Acquisitions
YoY Change
Other Investing Activities $60.15M $58.11M -$2.760M
YoY Change 141.18% -2205.43% -95.57%
Cash From Investing Activities $59.87M $57.87M -$3.070M
YoY Change 143.18% -1985.02% -95.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.420M -1.660M -480.0K
YoY Change -100.63% 245.83% -48.39%
NET CHANGE
Cash From Operating Activities -22.09M -15.52M -8.880M
Cash From Investing Activities 59.87M 57.87M -3.070M
Cash From Financing Activities -1.420M -1.660M -480.0K
Net Change In Cash 36.36M 40.69M -12.43M
YoY Change -84.62% -427.35% -81.16%
FREE CASH FLOW
Cash From Operating Activities -$22.09M -$15.52M -$8.880M
Capital Expenditures -$280.0K -$240.0K -$310.0K
Free Cash Flow -$21.81M -$15.28M -$8.570M
YoY Change 50.0% 78.3% 232.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0001370053
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26922000 shares
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27045000 shares
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27045000 shares
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
362-6295
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26922000 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27044527 shares
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
99000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
214000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37985
dei Entity Registrant Name
EntityRegistrantName
ANAPTYSBIO, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3828755
dei Entity Address Address Line1
EntityAddressAddressLine1
10421 Pacific Center Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
ANAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27047596 shares
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
146552000 USD
CY2018Q4 anab Research And Development Tax Incentive Credit Receivable Current
ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent
174000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
30623000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21836000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1105000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113596000 USD
CY2019Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
5000000 USD
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0 USD
CY2019Q2 anab Research And Development Tax Incentive Credit Receivable Current
ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent
0 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
275664000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
313486000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3772000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6960000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
430988000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
434216000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1481000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1445000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
45707000 USD
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
73128000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1913000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
148000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
60000 USD
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
60000 USD
CY2019Q2 us-gaap Assets
Assets
480149000 USD
CY2018Q4 us-gaap Assets
Assets
508997000 USD
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
10921000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5443000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14102000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8761000 USD
CY2019Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4781000 USD
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7574000 USD
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
819000 USD
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
58000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
796000 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
27000 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
640550000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
633251000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
574000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-223000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192730000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146690000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
448421000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
486365000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
480149000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
508997000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000000 USD
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27350000 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10583000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47981000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22393000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4307000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3832000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8448000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7779000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
31657000 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
14415000 USD
us-gaap Operating Expenses
OperatingExpenses
56429000 USD
us-gaap Operating Expenses
OperatingExpenses
30172000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26657000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14415000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-51429000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-30172000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
281000 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
436000 USD
us-gaap Interest Expense
InterestExpense
601000 USD
us-gaap Interest Expense
InterestExpense
887000 USD
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2957000 USD
CY2018Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1297000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5945000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2482000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-127000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2635000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
797000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5310000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
574000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2867000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
427000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1468000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-24022000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13618000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46119000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-28704000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-60000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23962000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13618000 USD
us-gaap Net Income Loss
NetIncomeLoss
-46040000 USD
us-gaap Net Income Loss
NetIncomeLoss
-28704000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
370000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
124000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
797000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-250000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23592000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13494000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45243000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28954000 USD
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.70
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27026000 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23932000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27004000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23867000 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
486365000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-22078000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
468155000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3643000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
370000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23962000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
448421000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
307581000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000 USD
CY2018Q1 anab Stock Issued During Period Value Due To Warrants Exercised
StockIssuedDuringPeriodValueDueToWarrantsExercised
75000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31616000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21356000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
132313000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
90411000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
5000000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-174000 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-1449000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1435000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1186000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
12660000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2097000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2260000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-375000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-15086000 USD
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
294527000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1397000 USD
CY2018Q2 anab Stock Issued During Period Value Due To Warrants Exercised
StockIssuedDuringPeriodValueDueToWarrantsExercised
1000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2548000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
124000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13618000 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
284979000 USD
us-gaap Net Income Loss
NetIncomeLoss
-46040000 USD
us-gaap Net Income Loss
NetIncomeLoss
-28704000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
239000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
118000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
6510000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
4808000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1926000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
255000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-332000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-317000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
200267000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
90031000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
421000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
536000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67533000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-916000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
789000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1469000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
76000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3750000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3125000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
280000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2961000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1860000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32956000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-24132000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113656000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81249000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146612000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57117000 USD
us-gaap Interest Paid Net
InterestPaidNet
301000 USD
us-gaap Interest Paid Net
InterestPaidNet
585000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
194000 USD
us-gaap Nature Of Operations
NatureOfOperations
Description of the Business <div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates using our proprietary, antibody discovery technology platform, which is designed to replicate, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">, the natural process of antibody generation. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</span></div>
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2525000 shares
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2542000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2443000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2576000 shares
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5910000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5642000 USD
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4429000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4197000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1481000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1445000 USD
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1909000 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2421000 USD
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
496000 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
442000 USD
CY2019Q2 anab Accrued Research And Contract Manufacturing Expenses Current
AccruedResearchAndContractManufacturingExpensesCurrent
11360000 USD
CY2018Q4 anab Accrued Research And Contract Manufacturing Expenses Current
AccruedResearchAndContractManufacturingExpensesCurrent
5577000 USD
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
337000 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14102000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8761000 USD
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27044527 shares
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
325580000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
862000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
326422000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2512033 shares
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5852778 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2152455 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
539400 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
69.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
122705 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
57117 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
69.45
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2512033 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
36.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M7D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70414000 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1398990 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y21D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
57308000 USD
CY2019Q2 anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
3643000 USD
CY2018Q2 anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
2548000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
6510000 USD
anab Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims
SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims
4808000 USD
CY2019Q2 anab Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options
EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions
37700000 USD
anab Lessee Operating Lease Number
LesseeOperatingLeaseNumber
2 lease
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P2Y3M
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0859
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2632000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1764000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
819000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1105000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
440000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
463000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
474000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
968000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
677000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2119000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
195000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1924000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
937000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
969000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
726000 USD

Files In Submission

Name View Source Status
0001370053-19-000027-index-headers.html Edgar Link pending
0001370053-19-000027-index.html Edgar Link pending
0001370053-19-000027.txt Edgar Link pending
0001370053-19-000027-xbrl.zip Edgar Link pending
anab-20190630.xsd Edgar Link pending
anab-20190630_cal.xml Edgar Link unprocessable
anab-20190630_def.xml Edgar Link unprocessable
anab-20190630_lab.xml Edgar Link unprocessable
anab-20190630_pre.xml Edgar Link unprocessable
anab-63019x10q.htm Edgar Link pending
anab-63019x10qxexx311.htm Edgar Link pending
anab-63019x10qxexx312.htm Edgar Link pending
anab-63019x10qxexx321.htm Edgar Link pending
anab-63019x10qxexx322.htm Edgar Link pending
anab-63019x10q_htm.xml Edgar Link completed
anabpipelinechartaug2019a01.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending